Pharmacological ascorbate as a novel therapeutic strategy to enhance cancer immunotherapy

Amira Zaher; Laura M Stephens; Ann M Miller; Stacey M Hartwig; Jeffrey M Stolwijk; Michael S Petronek; Zeb R Zacharias; Thaddeus J Wadas; Varun Monga; Joseph J Cullen; Muhammad Furqan; Jon C D Houtman; Steven M Varga; Douglas R Spitz; Bryan G Allen

doi:10.3389/fimmu.2022.989000

Back

Pharmacological ascorbate as a novel therapeutic strategy to enhance cancer immunotherapy

Journal article

Open access

Peer reviewed

Pharmacological ascorbate as a novel therapeutic strategy to enhance cancer immunotherapy

Amira Zaher, Laura M Stephens, Ann M Miller, Stacey M Hartwig, Jeffrey M Stolwijk, Michael S Petronek, Zeb R Zacharias, Thaddeus J Wadas, Varun Monga, Joseph J Cullen, …

Frontiers in immunology, Vol.13, pp.989000-989000

01/01/2022

DOI: 10.3389/fimmu.2022.989000

PMCID: PMC9444023

PMID: 36072595

Files and links (1)

url

https://doi.org/10.3389/fimmu.2022.989000View

Published (Version of record) Open Access

Abstract

Pharmacological ascorbate (i.e., intravenous infusions of vitamin C reaching ~ 20 mM in plasma) is under active investigation as an adjuvant to standard of care anti-cancer treatments due to its dual redox roles as an antioxidant in normal tissues and as a prooxidant in malignant tissues. Immune checkpoint inhibitors (ICIs) are highly promising therapies for many cancer patients but face several challenges including low response rates, primary or acquired resistance, and toxicity. Ascorbate modulates both innate and adaptive immune functions and plays a key role in maintaining the balance between pro and anti-inflammatory states. Furthermore, the success of pharmacological ascorbate as a radiosensitizer and a chemosensitizer in pre-clinical studies and early phase clinical trials suggests that it may also enhance the efficacy and expand the benefits of ICIs.

Details

Title: Subtitle: Pharmacological ascorbate as a novel therapeutic strategy to enhance cancer immunotherapy
Creators: Amira Zaher - Holden
Laura M Stephens
Ann M Miller
Stacey M Hartwig
Jeffrey M Stolwijk
Michael S Petronek
Zeb R Zacharias
Thaddeus J Wadas
Varun Monga
Joseph J Cullen
Muhammad Furqan
Jon C D Houtman
Steven M Varga
Douglas R Spitz
Bryan G Allen
Resource Type: Journal article
Publication Details: Frontiers in immunology, Vol.13, pp.989000-989000
DOI: 10.3389/fimmu.2022.989000
PMID: 36072595
PMCID: PMC9444023
NLM abbreviation: Front Immunol
eISSN: 1664-3224
Language: English
Date published: 01/01/2022
Academic Unit: Radiology; Graduate College Admin and Gen; Microbiology and Immunology; Hematology, Oncology, and Blood & Marrow Transplantation; Pathology; Iowa Neuroscience Institute; Surgery; Radiation Oncology; Radiation Research Laboratory; Fraternal Order of Eagles Diabetes Research Center; Internal Medicine
Record Identifier: 9984297430002771

Metrics

30 Record Views

15 Times Cited - Web of Science

See more details